Format

Send to

Choose Destination
Br J Clin Pharmacol. 2016 Aug;82(2):512-21. doi: 10.1111/bcp.12983. Epub 2016 Jun 8.

Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs.

Author information

1
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
2
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong.
3
Department of Mathematics and Statistics, Faculty of Mathematics, Computing and Technology, The Open University, Milton Keynes, Buckinghamshire, MK7 6AA, UK.
4
Research Department of Practice and Policy, School of Pharmacy, University College London, London, WC1N 1AX, UK.

Abstract

AIM:

Some previous studies suggest a long term association between clarithromycin use and cardiovascular events. This study investigates this association for clarithromycin given as part of Helicobacter pylori treatment (HPT).

METHODS:

Our source population was the Clinical Practice Research Datalink (CPRD), a UK primary care database. We conducted a self-controlled case series (SCCS), a case-time-control study (CTC) and a propensity score adjusted cohort study comparing the rate of cardiovascular events in the 3 years after exposure to HPT containing clarithromycin with exposure to clarithromycin free HPT. Outcomes were first incident diagnosis of myocardial infarction (MI), arrhythmia and stroke. For the cohort analysis we included secondary outcomes all cause and cardiovascular mortality.

RESULTS:

Twenty-eight thousand five hundred and fifty-two patients were included in the cohort. The incidence rate ratio of first MI within 1 year of exposure to HPT containing clarithromycin was 1.07 (95% CI 0.85, 1.34, P = 0.58) and within 90 days was 1.43 (95% CI 0.99, 2.09 P = 0.057) in the SCCS analysis. CTC and cohort results were consistent with these findings.

CONCLUSIONS:

There was some evidence for a short term association for first MI but none for a long term association for any outcome.

KEYWORDS:

adverse drug reaction; cardiovascular disease; clarithromycin; pharmacoepidemiology

PMID:
27090996
PMCID:
PMC4972168
DOI:
10.1111/bcp.12983
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center